Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
about
Cancer therapy with phytochemicals: evidence from clinical studiesSafety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parametersTriterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivoClinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancerDose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.Dose finding with longitudinal data: simpler models, richer outcomes.Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata).Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study.Differences in CD75s- and iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinomas and nontumoral liver tissues.Adaptive dose-finding studies: a review of model-guided phase I clinical trials.Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor ConsortiumHighly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.Emerging technologies to increase ligand binding assay sensitivityAn evidence-based systematic review of herb and supplement interactions by the Natural Standard Research Collaboration.Intravenous Mistletoe Treatment in Integrative Cancer Care: A Qualitative Study Exploring the Procedures, Concepts, and Observations of Expert Doctors.Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical researchA Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients.The case for mistletoe in the treatment of laryngeal cancer.A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.Detecting antigens by quantitative immuno-PCR.Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells.Molecular dynamics study of Pseudomonas aeruginosa lectin-II complexed with monosaccharides.Q56773631
P2860
Q26827407-EC3AE52B-15D0-49FE-9BE8-86946768FC51Q27002602-F7889AAC-C620-47FC-9CE1-968D5F1B576BQ27323005-B1B378F6-87AD-4A1E-85C5-0F4298A120AAQ30372504-16B4F840-B290-4D72-989D-A2DD382CE011Q30665810-E60502BB-5BB3-49DC-8949-EF6A725DCA5BQ30976631-89F595E7-A752-4E1C-AC55-E3D08A91454AQ33284261-BF7DC397-6110-4958-8D27-B0A25B7DD168Q33737284-BFB68803-98C9-437A-B934-807E74333A6BQ33767713-F2F8097F-D0E5-4EB7-9686-94C2F97D8312Q34001009-F2BC5274-E4C2-4B08-9D1B-E33719D5609CQ34292228-B9704D7D-0905-4641-8B4E-6048F48F6F43Q34486159-719254EA-CC3B-42D9-9911-C19A8D809DDEQ34871754-24C61CC9-73ED-4DA5-AC77-410D40E8442CQ36565068-3AC0F318-03EE-4424-B15E-25A89BC7D5C2Q36880805-D3D54DD0-9D16-400A-BD39-49F3DF98BE73Q37262806-F4D9E1D5-5EF7-4DE0-94AE-7A16623AC0AFQ37706106-6EC6375F-11DD-4DF4-9FB3-B908B801F6D7Q38189185-E585A013-3341-4080-8962-17F1E8A5820BQ42697628-93BBCC15-09E5-4680-8AEE-072942FBE998Q43517595-9A70389D-D128-4A12-87BA-4A7966F8A0BEQ44389468-1A9B7402-A566-4D0F-B6EF-02C7BB2A13E6Q46794956-B2FA7242-B56B-46D1-B774-6B6525FB52CAQ56773631-46B44265-CB99-4483-97CD-62EA227A2F4D
P2860
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Phase I trial of intravenous a ...... er New Drug Development Group.
@ast
Phase I trial of intravenous a ...... er New Drug Development Group.
@en
Phase I trial of intravenous a ...... er New Drug Development Group.
@en-gb
type
label
Phase I trial of intravenous a ...... er New Drug Development Group.
@ast
Phase I trial of intravenous a ...... er New Drug Development Group.
@en
Phase I trial of intravenous a ...... er New Drug Development Group.
@en-gb
prefLabel
Phase I trial of intravenous a ...... er New Drug Development Group.
@ast
Phase I trial of intravenous a ...... er New Drug Development Group.
@en
Phase I trial of intravenous a ...... er New Drug Development Group.
@en-gb
P2093
P356
P1433
P1476
Phase I trial of intravenous a ...... er New Drug Development Group.
@en
P2093
European Organization for Research and Treatment of Cancer New Drug Development Group
H Zwierzina
K Wilhelm-Ogunbiyi
P304
P356
10.1093/ANNONC/MDH469
P577
2004-12-01T00:00:00Z